File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Studies of SARS virus vaccines

TitleStudies of SARS virus vaccines
Authors
Issue Date2008
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43 How to Cite?
Abstract
1. Intranasal vaccination using inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant can induce strong systemic (serum immunoglobulin [Ig] G) and respiratory tract local (tracheal-lung wash fluid IgA) antibody responses with neutralising activity. 2. RBD-Fc (protein-based vaccine) is able to induce effective neutralising antibodies able to provide protection from SARS-CoV infection in animal models. 3. A single dose of RBD-rAAV vaccination can induce adequate neutralising antibody against SARS-CoV infection. 4. Additional doses of vaccine increased the production of neutralising antibody 5-fold compared with a single dose. 5. RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. 6. Intranasal vaccination with RBD-rAAV induced local IgA and systemic IgG neutralising antibodies and specific T-cell responses, able to protect against SARS-CoV infection in animal models. 7. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses. 8. Overall, our findings suggest that the inactivated vaccine, RBD-Fc and RBD-rAAV, can be further developed into effective and safe vaccines against SARS and that intranasal vaccination may be the preferred route of administration.
Persistent Identifierhttp://hdl.handle.net/10722/157565
ISSN
2013 SCImago Journal Rankings: 0.293

 

Author Affiliations
  1. The University of Hong Kong
DC FieldValueLanguage
dc.contributor.authorZheng, BJen_US
dc.contributor.authorDu, LYen_US
dc.contributor.authorZhao, GYen_US
dc.contributor.authorLin, YPen_US
dc.contributor.authorSui, HYen_US
dc.contributor.authorChan, Cen_US
dc.contributor.authorMa, Sen_US
dc.contributor.authorGuan, Yen_US
dc.contributor.authorYuen, KYen_US
dc.date.accessioned2012-08-08T08:51:18Z-
dc.date.available2012-08-08T08:51:18Z-
dc.date.issued2008en_US
dc.identifier.citationHong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43en_US
dc.identifier.issn1024-2708en_US
dc.identifier.urihttp://hdl.handle.net/10722/157565-
dc.description.abstract1. Intranasal vaccination using inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant can induce strong systemic (serum immunoglobulin [Ig] G) and respiratory tract local (tracheal-lung wash fluid IgA) antibody responses with neutralising activity. 2. RBD-Fc (protein-based vaccine) is able to induce effective neutralising antibodies able to provide protection from SARS-CoV infection in animal models. 3. A single dose of RBD-rAAV vaccination can induce adequate neutralising antibody against SARS-CoV infection. 4. Additional doses of vaccine increased the production of neutralising antibody 5-fold compared with a single dose. 5. RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. 6. Intranasal vaccination with RBD-rAAV induced local IgA and systemic IgG neutralising antibodies and specific T-cell responses, able to protect against SARS-CoV infection in animal models. 7. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses. 8. Overall, our findings suggest that the inactivated vaccine, RBD-Fc and RBD-rAAV, can be further developed into effective and safe vaccines against SARS and that intranasal vaccination may be the preferred route of administration.en_US
dc.languageengen_US
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_US
dc.relation.ispartofHong Kong Medical Journalen_US
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Medical Association.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAdministration, Intranasalen_US
dc.subject.meshAnimalsen_US
dc.subject.meshCommunicable Disease Controlen_US
dc.subject.meshDisease Models, Animalen_US
dc.subject.meshDisease Outbreaks - Prevention & Controlen_US
dc.subject.meshFemaleen_US
dc.subject.meshForecastingen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intramuscularen_US
dc.subject.meshMaleen_US
dc.subject.meshMiceen_US
dc.subject.meshPredictive Value Of Testsen_US
dc.subject.meshRisk Assessmenten_US
dc.subject.meshSars Virus - Immunologyen_US
dc.subject.meshSevere Acute Respiratory Syndrome - Epidemiology - Immunology - Prevention & Controlen_US
dc.subject.meshVaccination - Statistics & Numerical Dataen_US
dc.subject.meshVaccines, Inactivated - Administration & Dosageen_US
dc.subject.meshViral Vaccines - Administration & Dosage - Immunology - Pharmacologyen_US
dc.titleStudies of SARS virus vaccinesen_US
dc.typeArticleen_US
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_US
dc.identifier.emailGuan, Y:yguan@hkucc.hku.hken_US
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_US
dc.identifier.authorityZheng, BJ=rp00353en_US
dc.identifier.authorityGuan, Y=rp00397en_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.description.naturepublished_or_final_versionen_US
dc.identifier.pmid18708674en_US
dc.identifier.scopuseid_2-s2.0-70449859520en_US
dc.identifier.hkuros156461-
dc.identifier.volume14en_US
dc.identifier.issuesuppl. 4-
dc.identifier.spage39en_US
dc.identifier.epage43en_US
dc.publisher.placeHong Kongen_US
dc.identifier.scopusauthoridZheng, BJ=7201780588en_US
dc.identifier.scopusauthoridDu, LY=8686996200en_US
dc.identifier.scopusauthoridZhao, GY=8684553000en_US
dc.identifier.scopusauthoridLin, YP=8591935100en_US
dc.identifier.scopusauthoridSui, HY=23971615600en_US
dc.identifier.scopusauthoridChan, C=7404813960en_US
dc.identifier.scopusauthoridMa, S=8673195200en_US
dc.identifier.scopusauthoridGuan, Y=7202924055en_US
dc.identifier.scopusauthoridYuen, KY=36078079100en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats